Masuo Kurono

Summary

Affiliation: Dainippon Sumitomo Pharma Co
Country: Japan

Publications

  1. ncbi Backbone resonance assignments for the periplasmic chaperone LolA from Escherichia coli
    Shingo Nakada
    Genomic Science Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Enoki, Suita, Osaka 564 0053, Japan
    Biomol NMR Assign 1:125-7. 2007
  2. ncbi Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability
    Masuo Kurono
    Chemistry Research Laboratories, Dainippon Pharmaceutical Co Ltd, Enoki 33 94, Suita, Osaka 564 0053, Japan
    Biochem Pharmacol 71:338-53. 2006
  3. ncbi Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme
    Masuo Kurono
    Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Enoki 33 94, Suita, Osaka 564 0053, Japan
    J Pharm Sci 97:1468-83. 2008
  4. ncbi Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux
    Takafumi Matsumoto
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Japan
    J Pharmacol Sci 109:203-10. 2009
  5. ncbi Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats
    Takafumi Matsumoto
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Osaka, Japan
    J Pharmacol Sci 107:231-7. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Backbone resonance assignments for the periplasmic chaperone LolA from Escherichia coli
    Shingo Nakada
    Genomic Science Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Enoki, Suita, Osaka 564 0053, Japan
    Biomol NMR Assign 1:125-7. 2007
    ..We established backbone resonance assignments of 2H/13C/15N labeled LolA from Escherichia coli...
  2. ncbi Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability
    Masuo Kurono
    Chemistry Research Laboratories, Dainippon Pharmaceutical Co Ltd, Enoki 33 94, Suita, Osaka 564 0053, Japan
    Biochem Pharmacol 71:338-53. 2006
    ....
  3. ncbi Stability and hydrolysis kinetics of spirosuccinimide type inhibitors of aldose reductase in aqueous solution and retardation of their hydrolysis by the target enzyme
    Masuo Kurono
    Chemistry Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Enoki 33 94, Suita, Osaka 564 0053, Japan
    J Pharm Sci 97:1468-83. 2008
    ....
  4. ncbi Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux
    Takafumi Matsumoto
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Japan
    J Pharmacol Sci 109:203-10. 2009
    ..This improvement correlated with the decrease of sorbitol and fructose levels in the rat sciatic nerves. These findings indicate that ranirestat improves MNCV via normalization of sorbitol and fructose accumulation in the sciatic nerve...
  5. ncbi Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats
    Takafumi Matsumoto
    Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co, Ltd, Osaka, Japan
    J Pharmacol Sci 107:231-7. 2008
    ....